Oral THU-decitabine for MDS that has returned or not improved
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests an oral combination of two drugs (THU and decitabine) for people with myelodysplastic syndromes (MDS) whose disease has come back or not responded to at least one prior standard treatment. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have MDS that has returned or not gotten better after at least one prior standard treatment.
- You must be 18 years old or older.
- You must be able to get around and care for yourself (ECOG score of 3 or less).
- Your weight must be at least 41 kilograms (about 90 pounds).
- You must not have had treatment with decitabine (given by IV or as a pill) for 4 or more 28-day cycles before.
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must agree to use birth control while on the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.